Clal Bio Surges Most in Two Weeks as Unit Gets FDA Approval

Clal Biotechnology Industries Ltd. (CBI) advanced the most in two weeks after a unit got the U.S. Food and Drug Administration orphan drug status for its DiaPep277 treatment for juvenile diabetes.

The shares of the investment company advanced 4.9 percent, the most since May 8, to 13.06 shekels at 11:13 a.m. in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.